Susanne Schorsch


Susanne joined Amadeus in 2023 and is a Partner in Amadeus’ European early-growth deep tech strategy.

She is a professional venture capital investor and angel since 2014 and has led and co-led more than 20 investments in deeptech including health and biotech.

Susanne was previously a Partner at Verve Ventures. She has served as board member or observer on several of her portfolio companies such as: CREAL, a leader in lightfield technology for VR and AR; antibody discovery platform MemoTherapeutics; high throughput organism-on-chip animal testing alternative Nagi Bioscience; retinal biomarker company Earlysight, AI assisted diagnostics provider Medimaps; breakthrough oral delivery system plaform Biograil and next generation gene therapy company Somagenetix.

Susanne’s investments also include social impact software player Alaya, (tradesale to Benevity in 2021), neuromodulation powerhouse Onward (IPO in 2021, as well as IoT enabling nano-satellite company Astrocast (IPO in 2021)

Prior to her venture career, Susanne was a successful international business executive for 15 years. She headed BASF’s Global Additives Business and was responsible for Strategy and Innovation of BASF Performance Chemical Division. Her experience spans from developing and steering businesses to innovation and business strategy development for different industries and end-user applications.

Susanne has completed executive education programmes in Venture Capital and Innovation Organization at the UC Berkeley Haas School of Business. She holds an MSc and BSc in Industrial Engineering from the Karlsruhe Institute of Technology, and is an alumna of the University of Pennsylvania’s Wharton School.